In­ter­cept to sell in $800M cash buy­out af­ter sec­ond NASH re­jec­tion sank hopes

In­ter­cept Phar­ma­ceu­ti­cals plans to hand over its liv­er dis­ease drug Ocali­va and oth­er pipeline projects to Ital­ian phar­ma Al­fasig­ma in a $19 per-share cash deal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER